• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Labcorp Holdings Inc.

    5/29/25 4:05:23 PM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    S-8 POS 1 d856036ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on May 29, 2025

    Registration No. 333-279514

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT (333-279514)

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Labcorp Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   99-2588107

    (State or other jurisdiction of

    incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    358 South Main Street, Burlington, North Carolina   27215
    (Address of Principal Executive Offices)   (Zip Code)

    Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan

    (Full titles of the plans)

    Sandra D. van der Vaart

    Executive Vice President, Chief Legal Officer and Corporate Secretary

    Labcorp Holdings Inc.

    358 South Main Street

    Burlington, North Carolina 27215

    (Name and address of agent for service)

    (336) 229-1127

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    William I. Intner

    Hogan Lovells US LLP

    100 International Drive, Suite 2000

    Baltimore, Maryland 21202

    (410) 659-2700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment No. 1”) relates to the Registration Statement on Form S-8 (File No. 333-279514) (the “Registration Statement”) filed with the Securities and Exchange Commission by Labcorp Holdings Inc. (the “Company”) and is being filed to deregister only those shares of the Company’s common stock, par value $0.10 per share (“Common Stock”), issuable pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan (the “Plan”) that were registered under the Registration Statement and remain unissued or unsold thereunder.

    The Company is no longer offering its securities under the Plan. Thus, in accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offering, the Company hereby removes from registration any shares of Common Stock registered under the Registration Statement issuable pursuant to the Plan which remain unissued or unsold as of May 15, 2025. Although any shares of Common Stock issuable pursuant to the Plan are being deregistered, this Post-Effective Amendment No. 1 shall not serve to reduce the number of shares of Common Stock covered by the Registration Statement and issuable pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlington, State of North Carolina, on May 29, 2025.

     

    LABCORP HOLDINGS INC.
    By:  

    /s/ Sandra D. van der Vaart

      Sandra D. van der Vaart
      Executive Vice President, Chief Legal Officer and Corporate Secretary

    No other person is required to sign this Post-Effective Amendment No. 1 in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $LH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Kerrii B sold $132,500 worth of shares (500 units at $265.00), decreasing direct ownership by 4% to 12,166 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      7/2/25 10:37:22 AM ET
      $LH
      Medical Specialities
      Health Care
    • Director Anderson Kerrii B sold $130,000 worth of shares (500 units at $260.00), decreasing direct ownership by 4% to 12,666 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      6/12/25 10:07:20 AM ET
      $LH
      Medical Specialities
      Health Care
    • EVP, Pres of ED, CMO & CSO Caveney Brian J sold $494,000 worth of shares (2,000 units at $247.00), decreasing direct ownership by 6% to 30,067 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      6/5/25 8:19:38 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and

      7/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

      ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

      7/8/25 9:00:00 AM ET
      $LH
      $PRVA
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • Labcorp to Announce Second Quarter Financial Results on July 24, 2025

      BURLINGTON, N.C., June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

      6/26/25 4:10:00 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

      7/10/25 9:03:30 AM ET
      $LH
      Medical Specialities
      Health Care
    • Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

      Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

      4/2/25 8:50:29 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Citigroup with a new price target

      Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

      3/4/25 7:36:42 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    SEC Filings

    See more
    • Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      7/10/25 6:58:16 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      6/27/25 4:16:25 PM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      6/26/25 4:12:43 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Financials

    Live finance-specific insights

    See more
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and

      7/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp to Announce Second Quarter Financial Results on July 24, 2025

      BURLINGTON, N.C., June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

      6/26/25 4:10:00 PM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Announces 2025 First Quarter Results

      Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:Revenue guidance of 6.7% to 8.0%Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05Free Cash Flow of $1.10 billion to $1.25 billionProviding broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-dateIntroduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid

      4/29/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    See more
    • Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

      ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

      7/8/25 9:00:00 AM ET
      $LH
      $PRVA
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

      SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

      5/12/25 9:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

      SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

      2/13/24 5:08:06 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

      SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

      7/24/23 4:20:26 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

      2/10/21 11:14:27 AM ET
      $LH
      Medical Specialities
      Health Care